<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8076">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00859027</url>
  </required_header>
  <id_info>
    <org_study_id>02-062</org_study_id>
    <secondary_id>GCRC # 413</secondary_id>
    <nct_id>NCT00859027</nct_id>
  </id_info>
  <brief_title>Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer</brief_title>
  <official_title>The Effect Of Risedronate On Bone Turnover And Bone Mass In Older Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Connecticut Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Proctor and Gamble/Aventis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Connecticut Health Center</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Men treated with neoadjuvant luteinizing hormone-releasing hormone (LHRH)-agonists such as
      leuprolide and goserelin for prostate cancer will become hypogonadal due to hormonal
      suppression and demonstrate increased bone turnover and consequent bone loss at the hip and
      spine. This bone loss can be prevented by treatment with 35 mg/week of risedronate.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Bone Mineral Density at Spine at Baseline Bone Mineral Density at Spine at 6 Months</measure>
    <time_frame>% change in BMD at 6 months compared to baseline values at spine and hip</time_frame>
    <safety_issue>No</safety_issue>
    <description>BMD measurement is mean % change of group compared with baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bone Turnover Markers</measure>
    <time_frame>6 and 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Risedronate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>35 mg by mouth every week as directed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Calcium and vitamin D</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>risedronate</intervention_name>
    <description>35 mg/week by mouth</description>
    <arm_group_label>Risedronate</arm_group_label>
    <other_name>Actonel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>One tablet by mouth every week as directed</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-metastatic prostate cancer

          -  Men to receive Gonadotropin-releasing Hormone-agonist therapy

        Exclusion Criteria:

          -  Other cancers except skin cancer

          -  Evidence of metabolic bone disease

          -  Prior use of bisphosphonates
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pamela Taxel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Connecticut Health Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Connecticut Health Center</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 28, 2013</lastchanged_date>
  <firstreceived_date>March 7, 2009</firstreceived_date>
  <firstreceived_results_date>August 22, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Connecticut Health Center</investigator_affiliation>
    <investigator_full_name>Pamela Taxel</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Non-metastatic</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Risedronic acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects recruited from medical clinics/ urology clinics.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Risedronate 35 mg p.o.Every Week Plus Calcium and Vit D Daily</title>
        </group>
        <group group_id="P2">
          <title>Calcium and Vitamin D Daily (Placebo Group)</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Risedronate Plus Calcium and Vit D</title>
        </group>
        <group group_id="B2">
          <title>Calcium and Vitamin D</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
                <measurement group_id="B2" value="25"/>
                <measurement group_id="B3" value="50"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="17"/>
                <measurement group_id="B2" value="18"/>
                <measurement group_id="B3" value="35"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
                <measurement group_id="B2" value="7"/>
                <measurement group_id="B3" value="15"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="70" spread="9"/>
                <measurement group_id="B2" value="72" spread="7"/>
                <measurement group_id="B3" value="71" spread="8"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
                <measurement group_id="B2" value="25"/>
                <measurement group_id="B3" value="50"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
                <measurement group_id="B2" value="25"/>
                <measurement group_id="B3" value="50"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Bone Mineral Density at Spine at Baseline Bone Mineral Density at Spine at 6 Months</title>
        <description>BMD measurement is mean % change of group compared with baseline</description>
        <time_frame>% change in BMD at 6 months compared to baseline values at spine and hip</time_frame>
        <safety_issue>No</safety_issue>
        <population>The number that completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Risedronate - Spine</title>
          </group>
          <group group_id="O2">
            <title>Calcium and Vitamin D-Spine</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="20"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Bone Mineral Density at Spine at Baseline Bone Mineral Density at Spine at 6 Months</title>
            <description>BMD measurement is mean % change of group compared with baseline</description>
            <units>percentage change of BMD from baseline</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.7" spread="0.77"/>
                  <measurement group_id="O2" value="0" spread="1.35"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Turnover Markers</title>
        <time_frame>6 and 12 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>CAlcium and Vitamin D</title>
        </group>
        <group group_id="E2">
          <title>Risedronate</title>
          <description>Particiapnts given 35 mg by mouth every week</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small number but otherwise no limitations.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Pamela Taxel MD</name_or_title>
      <organization>University of Connecticut Health Center</organization>
      <phone>860-679-4743</phone>
      <email>taxel@nso.uchc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
